Mesoblast's Neofuse Stem Cell Product Shows Positive Results in Phase 2 Lumbar Spinal Fusion Trial

Key points: Phase 2 trial results using Mesoblast's allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells demonstrated rates of fusion success that were comparable to the gold standard bone autograft MPCs were well tolerated with no cell-related serious adverse events and no evidence of any ectopic bone formation At 12 months, fusion was ... (more)

http://www.drugs.com/clinical_trials/mesoblast-s-neofuse-stem-cell-product-shows-positive-results-phase-2-lumbar-spinal-fusion-trial-15025.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+Drugscom-ClinicalTrials+%28Drugs.com+-+Clinical+Trials%29